4D Molecular Therapeutics (NASDAQ:FDMT) Lowered to Sell Rating by Wall Street Zen

4D Molecular Therapeutics (NASDAQ:FDMT) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Other research analysts have also recently issued research reports about the company. Chardan Capital lifted their target price on 4D Molecular Therapeutics from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Royal Bank Of Canada upped their target price on shares of 4D Molecular Therapeutics from $26.00 to $32.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 11th. Roth Capital lowered their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, August 12th. Finally, Barclays cut their price target on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $28.70.

4D Molecular Therapeutics Trading Down 4.4%

4D Molecular Therapeutics stock opened at $10.70 on Friday. The firm has a market capitalization of $611.29 million, a price-to-earnings ratio of -2.85 and a beta of 2.96. The firm’s fifty day moving average price is $10.37 and its two-hundred day moving average price is $7.03. 4D Molecular Therapeutics has a 1-year low of $2.23 and a 1-year high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Monday, November 10th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.01. The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.40 million. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. On average, research analysts forecast that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Insider Buying and Selling

In related news, insider Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $12.00, for a total value of $32,136.00. Following the completion of the transaction, the insider directly owned 3,594 shares in the company, valued at approximately $43,128. The trade was a 42.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 10,763 shares of company stock valued at $109,415. 9.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds have recently made changes to their positions in FDMT. Dynamic Technology Lab Private Ltd bought a new stake in shares of 4D Molecular Therapeutics during the 1st quarter valued at $39,000. Wexford Capital LP purchased a new position in 4D Molecular Therapeutics during the 3rd quarter valued at about $41,000. Los Angeles Capital Management LLC bought a new stake in shares of 4D Molecular Therapeutics during the second quarter valued at about $42,000. Quadrature Capital Ltd purchased a new stake in shares of 4D Molecular Therapeutics in the second quarter worth about $42,000. Finally, Farther Finance Advisors LLC boosted its position in shares of 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after acquiring an additional 2,674 shares during the period. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.